Body dysmorphic disorder

Body dysmorphic disorder: GP guide to diagnosis, treatment, and BDDQ screening

By Dr HB Lo, FACRRM 8 min read

Body dysmorphic disorder (BDD) is an OCD-spectrum condition defined by preoccupation with a perceived appearance defect that others see as absent or minor, combined with repetitive behaviours (mirror-checking, grooming, reassurance-seeking) consuming ≥1 hour per day. AU prevalence is ~2%; suicidal ideation occurs in ~80% of those affected.

First-line treatment is CBT-BDD with exposure and response prevention, and/or high-dose SSRI (fluoxetine 40–80 mg, sertraline 150–200 mg) for 12 weeks at maximum tolerated dose. GPs must screen with the BDDQ before any cosmetic-procedure referral under AHPRA's July 2023 cosmetic-surgery guidelines.

What body dysmorphic disorder is

Body dysmorphic disorder (BDD) is an OCD-spectrum condition in which a person is preoccupied with a perceived defect or flaw in their physical appearance that is not observable or appears only slight to others. This preoccupation drives repetitive behaviours — mirror-checking, excessive grooming, skin-picking, reassurance-seeking, or mental comparisons — that consume at least one hour per day and cause significant distress or functional impairment.

BDD affects approximately 2% of Australians across their lifetime. The male-to-female ratio is roughly equal, though muscle dysmorphia (preoccupation with perceived inadequate muscularity) predominates in men. Peak onset is in adolescence, mean age around 16, and the course is chronic without treatment. Diagnostic delay commonly exceeds ten years, largely because people present to dermatologists, cosmetic practitioners, and orthodontists rather than to mental-health services.

Suicidality is a central concern. Approximately 80% of people with BDD experience lifetime suicidal ideation, 24–28% have made attempts, and completed-suicide rates are markedly elevated compared with the general population. This makes every BDD consult a suicidality screen.

A. Core clinical — the AU general practice framework

Recognising BDD

BDD is under-recognised in general practice. The clinical picture to look for:

  • Repeated requests for cosmetic-procedure referrals — skin, nose, hair, teeth, stomach, or other body areas
  • Repeated dermatology or plastic-surgery attendances with ongoing dissatisfaction after procedures
  • Excessive time in front of mirrors or deliberate mirror-avoidance
  • Camouflaging behaviours — specific clothing, hats, heavy make-up, posture
  • Significant functional impairment — avoidance of work, study, or social situations due to appearance concerns
  • High suicidality out of proportion to apparent circumstances
  • Men presenting with body-building concerns plus anabolic-androgenic steroid (AAS) use (muscle dysmorphia)

DSM-5-TR criteria require: (A) preoccupation with a perceived defect not observable or appearing only slight to others; (B) repetitive behaviours or mental acts in response to appearance concerns; (C) clinically significant distress or impairment; (D) not better explained by concerns with body fat or weight in an eating disorder.

About 30–40% of patients have poor or absent insight — they genuinely believe the defect is real and visible. These patients are at highest risk of harm and require urgent psychiatric assessment.

Screening with the BDDQ

The BDDQ (Phillips Body Dysmorphic Disorder Questionnaire) is a free, four-item self-report tool with approximately 94% sensitivity and 90% specificity. Use the BDDQ-DV (dermatology version) in cosmetic or skin-focused settings.

Offer the BDDQ before any cosmetic-procedure referral. AHPRA’s July 2023 cosmetic-surgery guidelines mandate pre-procedure mental-health assessment — a documented BDDQ screen and referral to mental health first is now expected clinical practice. Failure to screen carries medico-legal exposure.

History and workup

Comprehensive history:

  • Body-part focus, time spent in appearance preoccupations per day, specific repetitive behaviours
  • Functional impact — work, study, relationships, intimate life, social activities
  • Insight level — can they acknowledge others might not see the defect?
  • Suicidality — direct enquiry at every visit; use the Columbia Suicide Severity Rating Scale
  • Cosmetic procedures sought and received — note dissatisfaction patterns
  • AAS or other substance use (muscle dysmorphia)
  • Family psychiatric history

Comorbidity screens: PHQ-9 (depression), GAD-7 (anxiety), SCOFF (eating disorder), AUDIT-C (alcohol use).

Investigations: FBC, UEC, LFTs, TFTs, vitamin D, B12, folate, iron studies, fasting glucose. Urine drug screen if substance use is suspected. In muscle dysmorphia, add testosterone, LH/FSH, lipid profile, LFTs, haematocrit, and ECG if high-dose AAS use is suspected.

Differential diagnosis

Key differentials:

  • Eating disorder — weight and shape concerns dominate; if both weight/shape and separate appearance preoccupation coexist, both diagnoses may apply
  • OCD — compulsions on non-appearance themes; BDD is coded when appearance is the primary focus
  • Social anxiety disorder — fear of negative evaluation generally; in BDD fear is specifically about appearance
  • Major depressive disorder — rumination on guilt or worthlessness rather than appearance
  • Schizophrenia/delusional disorder — when delusions extend beyond appearance

B. Evidence for CBT-BDD and SSRI

Cognitive behavioural therapy with ERP

The Veale 2014 meta-analysis of CBT-BDD with exposure and response prevention (ERP) — 16–22 weekly sessions — showed an effect size of approximately 1.2, with a response rate of around 70%. Effects are durable post-treatment. NICE CG31 recommends CBT-BDD as first-line.

CBT-BDD components:

  • Exposure exercises — approaching feared appearance-related situations without performing checking, grooming, or camouflaging behaviours
  • Response prevention — resisting the compulsive behaviour after exposure
  • Mirror retraining — controlled, non-evaluative mirror exposure to reduce both checking and complete avoidance
  • Cognitive restructuring — challenging appearance-related beliefs

Access in Australia is through a clinical psychologist trained in CBT-BDD, referred via a Mental Health Treatment Plan (MBS item 2715) — this unlocks up to 10 subsidised psychology sessions per year through the Better Access initiative. The Australian Psychological Society maintains a Find a Psychologist directory.

Waitlists for CBT-BDD-trained psychologists can be long. THIS WAY UP and similar online CBT platforms provide a useful bridge during waitlists for mild-to-moderate presentations; they are not substitutes for specialist-delivered therapy in severe cases.

High-dose SSRI

Phillips 2002 (Am J Psychiatry) demonstrated that fluoxetine at 60–80 mg/day produced a 53% response rate versus 18% with placebo, with higher doses performing better than lower doses. BDD consistently requires higher SSRI doses than typical depression.

Recommended doses:

  • Fluoxetine 40–80 mg/day
  • Sertraline 150–200 mg/day
  • Escitalopram 20–30 mg/day
  • Fluvoxamine 200–300 mg/day (PBS Authority for OCD — use parallels BDD)

A 12-week trial at maximum tolerated dose is required before declaring SSRI failure. Combination of CBT-BDD plus SSRI is superior to either alone in moderate-to-severe disease.

Second-line options (psychiatrist-led): clomipramine 25–250 mg/day (baseline ECG required — lethality risk in a high-suicidality population); atypical antipsychotic augmentation (aripiprazole, risperidone) for poor-insight or delusional subtypes.

Avoid: long-term benzodiazepines (mask CBT exposure work, dependence risk), reassurance-giving as an ongoing strategy, and St John’s wort (serotonergic interaction with SSRIs and clomipramine).

C. The cosmetic-procedure trap

Phillips 2001 (Am J Psychiatry) and subsequent series consistently show that approximately 90% of people with BDD report no improvement or worsening after cosmetic procedures. The focus of preoccupation frequently migrates to a different body part or a new feature of the treated area. Rare cases of aggression toward treating practitioners after dissatisfying procedures have been reported.

The AHPRA July 2023 cosmetic-surgery reforms require pre-procedure mental-health assessment from all practitioners in the cosmetic-surgery space. GPs are expected to:

  1. Administer the BDDQ before issuing any cosmetic-procedure referral
  2. Document the screen and the counselling provided
  3. Refer to mental-health services first when BDD is probable or confirmed
  4. Not issue a cosmetic referral as the primary response to a probable BDD presentation

This is both sound clinical practice and a medico-legal obligation.

D. Australian operations

MBS items

  • Level B/C/D consults — items 23, 36, 44
  • Mental Health Treatment Plan preparation — 2715; review — 2717
  • Psychology Better Access — 80000–80020 (10 + 10 + 2 sessions per year)
  • Psychiatrist initial/review — 105/106
  • Telehealth psychology — 91790 series (useful for rural patients and during waitlists)
  • GP Chronic Condition Management Plan — 965/967 for BDD with chronic mental and physical comorbidity
  • ECG — 11700 before clomipramine or high-dose QT-risk co-medication

PBS options

  • Fluoxetine, sertraline, escitalopram, paroxetine, clomipramine — PBS General Schedule
  • Fluvoxamine — PBS General Schedule and Authority Streamlined for OCD; BDD use is pragmatically parallel
  • Aripiprazole, risperidone — PBS Authority Required (for psychosis); off-label for BDD augmentation; private cost approximately $30–80 per month
  • Escitalopram above 20 mg and sertraline above 200 mg involve off-label prescribing; arrange private prescription at higher doses

Referral pathways

ReferralIndication
Clinical psychologist (CBT-BDD trained)First-line for most patients; via MHCP 2715
Psychiatrist (105/106)Poor insight, delusional, paediatric, severe suicidality, refractory, AAS complications
Headspace (12–25 years)Youth-friendly entry point
Acute mental-health team or EDActive suicidal plan or intent; post-procedure aggression
Sexual health or endocrinologyAAS-related hypogonadism or hepatotoxicity

Consumer resources

E. Special populations

Adolescents. BDD peak onset is adolescence. Social-media and beauty-filter exposure is associated with worsening body-image concerns; counsel reduction. Refer to Headspace for youth-friendly access. Parental education about BDD and family-accommodation reduction is part of treatment. Suicidality risk in adolescent BDD is very high — psychiatric review is standard for paediatric presentations.

Men with muscle dysmorphia. Preoccupation centres on being insufficiently muscular or lean. AAS use is common and carries risks of cardiomyopathy, hepatotoxicity, hypogonadism, mood instability, and dependence. Non-judgemental enquiry about AAS is part of the workup. Exercise prescription should be tailored with the psychologist — compulsive gym behaviours may need to be addressed within CBT-BDD.

DVA. Serving and ex-serving personnel are covered under DVA equivalent arrangements. Open Arms — Veterans & Families Counselling 1800 011 046 provides veteran-specific support.

When to escalate

Refer urgently to a psychiatrist or acute mental-health team when:

  • Active suicidal plan or recent attempt
  • Profound functional decline — housebound, unable to leave home
  • Aggressive behaviour toward treating practitioners following procedures
  • Poor or absent insight with severe distress
  • Paediatric or adolescent BDD
  • No response after adequate CBT-BDD trial and high-dose SSRI at maximum tolerated dose

Refer to a psychologist (not psychiatrist) when presentations are mild-to-moderate with adequate insight and no urgent suicidal risk.

What this article is and is not

This is general health information drawn from current Australian clinical guidelines — RANZCP OCD-spectrum CPG, Therapeutic Guidelines (eTG), AHPRA cosmetic-surgery guidelines, NICE CG31, and key international trials. It is not personal medical advice and does not create a doctor–patient relationship. Decisions about individual treatment — including medication choice and referral — are made between you and your own GP or treating clinician.

For urgent support: Lifeline 13 11 14, Beyond Blue 1300 22 4636, Suicide Call Back Service 1300 659 467. For consumer information: HealthDirect, Better Health Channel, BDD Foundation.

Sources cited

  1. Therapeutic Guidelines (eTG) — Psychotropic
  2. RANZCP — OCD-spectrum clinical practice guidelines
  3. RACGP — OCD-spectrum in general practice
  4. AHPRA — Cosmetic surgery guidelines (July 2023)
  5. NICE CG31 — OCD and BDD
  6. Phillips KA — Body dysmorphic disorder (NEJM 2004)
  7. Veale D et al. — CBT-BDD meta-analysis (Behav Res Ther 2014)
  8. Phillips KA — Fluoxetine in BDD (Am J Psychiatry 2002)
  9. Phillips KA — Cosmetic procedure outcomes in BDD (Am J Psychiatry 2001)
  10. BDD Foundation — BDDQ tool
  11. Australian Psychological Society
  12. MBS Online

Frequently asked questions

  • How is BDD different from normal concerns about appearance?

    Everyone has appearance concerns at times. BDD is distinguished by the intensity and impact: preoccupations consuming at least one hour per day, repetitive checking or avoidance behaviours, and significant impairment in work, study, relationships, or daily function. The perceived defect is either absent entirely or appears only slight to outside observers. Around 30–40 % of people with BDD have poor or absent insight — they are genuinely convinced the defect is real and visible. Diagnostic delay in Australia commonly exceeds 10 years, partly because people present to dermatologists and cosmetic practitioners rather than to mental-health services.

  • Why shouldn't someone with BDD get the cosmetic procedure they want?

    Evidence consistently shows that approximately 90 % of people with BDD report no improvement or worsening of their BDD symptoms after cosmetic procedures, and the focus of preoccupation frequently shifts to a different body part afterwards. AHPRA's July 2023 cosmetic-surgery guidelines now mandate pre-procedure mental-health assessment, including a BDDQ screen. GPs who provide a cosmetic referral without documenting a BDD screen carry medico-legal exposure. Mental-health treatment first — CBT-BDD and SSRI — produces durable benefit that cosmetic intervention does not.

  • What is the BDDQ and when should I use it?

    The BDDQ (Phillips Body Dysmorphic Disorder Questionnaire) is a free four-item self-report screen with approximately 94 % sensitivity and 90 % specificity in community samples. A dermatology version (BDDQ-DV) exists for cosmetic or skin-focused settings. You should offer the BDDQ whenever you see a patient requesting a cosmetic-procedure referral, presenting with repeated appearance-related consultations to skin or body specialists, or whose presentation raises appearance preoccupation concerns. The BDDQ is available free at the BDD Foundation website.

  • Which SSRI dose is used for BDD — is it the same as for depression?

    BDD generally requires higher SSRI doses than typical depression. Target doses: fluoxetine 40–80 mg daily, sertraline 150–200 mg daily, escitalopram 20–30 mg daily, fluvoxamine 200–300 mg daily. A 12-week trial at maximum tolerated dose is required before concluding an SSRI has failed — much longer than the 4–6 weeks often used in depression. Combine with CBT-BDD for moderate to severe disease. Escitalopram above 20 mg and fluvoxamine are partially off-label for BDD in the PBS context, though both are used in specialist practice.

  • When does a GP refer to a psychiatrist rather than a psychologist?

    Refer to a psychiatrist when: the patient has poor or absent insight (delusional BDD), active or recent suicidal ideation, no response after an adequate CBT-BDD trial plus high-dose SSRI, significant anabolic-androgenic steroid (AAS) complications, paediatric or adolescent presentation, or requirement for off-label antipsychotic augmentation (aripiprazole, risperidone). For most patients without these features, a clinical psychologist trained in CBT-BDD and accessed via a Mental Health Treatment Plan is the appropriate first-line referral.

Source quality

Sources grouped by evidence tier. AU primary tier first; international where AU is silent or lagging; named-author reconstruction where guidelines have not yet caught up. How tiers work.